Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - EBioscience

  • GEN | Biolinks
    ... for Neglected Diseases Initiative DSM Duke University Duquesne University Dyomics eBioscience Economic Development Corporation of Utah Economic Development Partnership of Alabama ...
  • Affymetrix, PerkinElmer Cut Losses in Q4
    line-was results from eBioscience, the maker of flow cytometry and immunoassay reagent products that Affy acquired for $315 million cash in June. eBioscience accounted for $18.1 ...
    2-1-2013
  • eBioscience Sheds Western Blot Line
    acquiring the TrueBlot ® IP/Western blot product line from eBioscience for an undisclosed sum, less than a year after all of eBioscience was bought by Affymetrix for $315 million. ...
    12-13-2012
  • Affymetrix Drops Purchase Price for eBioscience to $315M
    Affymetrix will pay $315 million to take over eBioscience instead of $330 million as ... announced our original agreement with eBioscience last November," says Frank Witney, ...
    5-4-2012
  • Tools and Technologies to Advance Cell Biology Exhibited at ASCB
    ... InstantOne(tm) PhosphoELISA is a one-hour, single wash cell-signaling assay from eBioscience for the detection of total- and/or phospho-protein levels of a specific protein. The ...
    1-15-2012
  • This Year's M&As Among Life Science Tool Firms Show Interest...
    ... Affymetrix/eBioscience-$330 million On November 30, Affymetrix announced it intended to buy privately held eBioscience for $330 million, provider of flow cytometry and immunoassay ...
    12-28-2011
  • Affymetrix to Pay $330M to acquire eBioscience
    Affymetrix is buying San Diego-based eBioscience for $330 million in cash. eBioscience is specialized in the field of flow cytometry and immunoassay reagents for immunology and ...
    11-30-2011

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll